Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Rating)'s share price traded up 3.8% during mid-day trading on Wednesday . The stock traded as high as $1.64 and last traded at $1.62. 801 shares were traded during mid-day trading, a decline of 95% from the average session volume of 16,446 shares. The stock had previously closed at $1.56.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Friday, March 17th.

Armata Pharmaceuticals Stock Up 3.8 %

The company has a market cap of $58.53 million, a PE ratio of -1.49 and a beta of 1.18.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Rating) last announced its earnings results on Thursday, March 16th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.34 million. Armata Pharmaceuticals had a negative return on equity of 75.16% and a negative net margin of 670.26%. On average, equities analysts anticipate that Armata Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Institutional Trading of Armata Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Armata Pharmaceuticals by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 273,150 shares of the company's stock worth $1,335,000 after acquiring an additional 10,400 shares in the last quarter. Northern Trust Corp purchased a new position in Armata Pharmaceuticals during the first quarter worth approximately $95,000. Renaissance Technologies LLC increased its position in shares of Armata Pharmaceuticals by 5.6% in the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company's stock worth $91,000 after acquiring an additional 3,900 shares in the last quarter. HRT Financial LP acquired a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth $52,000. Finally, Jane Street Group LLC acquired a new stake in Armata Pharmaceuticals during the 4th quarter valued at $25,000. Institutional investors and hedge funds own 3.76% of the company's stock.

Armata Pharmaceuticals Company Profile

(Get Rating)

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Further Reading

• Get a free copy of the StockNews.com research report on Armata Pharmaceuticals (ARMP)
• ASML Reports Massive Growth, Management Points To Sluggish 2023
• Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
• Mullen Automotive: Is The Bloom Off The Rose?
• Diversified Abbott Laboratories Could Reverse And Move Higher
• Okta Reversal In Progress While Catalysts Approach

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.